PubMed registered articles Leonardo A. Meza-Zepeda

Publications by Leonardo A. Meza-Zepeda

109 publications found

Publications 2024

1. Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
   Evolutionary mode and timing of dissemination of high-grade serous carcinomas
   JCI Insight, 9 (3)
   DOI 10.1172/jci.insight.170423, PubMed 38175731
2. Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024)
   Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
   Nat Commun, 15 (1), 2810
   DOI 10.1038/s41467-024-47031-y, PubMed 38561347

Publications 2023

1. Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O, Clancy T (2023)
   The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
   Front Immunol, 14, 1226445
   DOI 10.3389/fimmu.2023.1226445, PubMed 37799721
2. Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M et al. (2023)
   Heritable defects in telomere and mitotic function selectively predispose to sarcomas
   Science, 379 (6629), 253-260
   DOI 10.1126/science.abj4784, PubMed 36656928
3. Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023)
   Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential
   Mol Oncol, 17 (11), 2432-2450
   DOI 10.1002/1878-0261.13514, PubMed 37622176

Publications 2022

1. Fiorito E, Szybowska P, Haugsten EM, Kostas M, Øy GF, Wiedlocha A, Singh S, Nakken S, Mælandsmo GM, Fletcher JA, Meza-Zepeda LA, Wesche J (2022)
   Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
   Br J Cancer, 127 (11), 1939-1953
   DOI 10.1038/s41416-022-01973-6, PubMed 36097178
2. Georgiesh T, Aggerholm-Pedersen N, Schöffski P, Zhang Y, Napolitano A, Bovée JVMG, Hjelle Å, Tang G, Spalek M, Nannini M, Swanson D, Baad-Hansen T, Sciot R, Hesla AC, Huang P, Dorleijn D, Haugland HK, Lacambra M, Skoczylas J, Pantaleo MA, Haas RL, Meza-Zepeda LA, Haller F, Czarnecka AM, Loong H et al. (2022)
   Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
   Br J Cancer, 127 (10), 1793-1798
   DOI 10.1038/s41416-022-01959-4, PubMed 36030294
3. Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
   Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
   Front Oncol, 12, 1040730
   DOI 10.3389/fonc.2022.1040730, PubMed 36523963
4. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
5. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
6. Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A (2022)
   Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
   Leukemia, 36 (7), 1887-1897
   DOI 10.1038/s41375-022-01597-y, PubMed 35643867
7. Namløs HM, Skårn M, Ahmed D, Grad I, Andresen K, Kresse SH, Munthe E, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind GE, Meza-Zepeda LA (2022)
   miR-486-5p expression is regulated by DNA methylation in osteosarcoma
   BMC Genomics, 23 (1), 142
   DOI 10.1186/s12864-022-08346-6, PubMed 35172717
8. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
   A national precision cancer medicine implementation initiative for Norway
   Nat Med, 28 (5), 885-887
   DOI 10.1038/s41591-022-01777-4, PubMed 35513529
9. Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022)
   Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
   Genome Med, 14 (1), 86
   DOI 10.1186/s13073-022-01090-2, PubMed 35948919

Publications 2021

1. Bengtsen M, Winje IM, Eftestøl E, Landskron J, Sun C, Nygård K, Domanska D, Millay DP, Meza-Zepeda LA, Gundersen K (2021)
   Comparing the epigenetic landscape in myonuclei purified with a PCM1 antibody from a fast/glycolytic and a slow/oxidative muscle
   PLoS Genet, 17 (11), e1009907
   DOI 10.1371/journal.pgen.1009907, PubMed 34752468
2. Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E (2021)
   Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
   Cancer Immunol Immunother, 70 (9), 2617-2624
   DOI 10.1007/s00262-021-02876-w, PubMed 33580363
3. Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021)
   Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour
   Pathology, 53 (6), 713-719
   DOI 10.1016/j.pathol.2020.11.010, PubMed 33745702
4. Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021)
   Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
   PLoS One, 16 (3), e0248140
   DOI 10.1371/journal.pone.0248140, PubMed 33690666
5. Hølmebakk T, Wiedswang AM, Meza-Zepeda LA, Hompland I, Lobmaier IVK, Berner JM, Stoldt S, Boye K (2021)
   Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
   Ann Surg Oncol, 28 (11), 6837-6845
   DOI 10.1245/s10434-021-09605-8, PubMed 33651216
6. Reint G, Li Z, Labun K, Keskitalo S, Soppa I, Mamia K, Tolo E, Szymanska M, Meza-Zepeda LA, Lorenz S, Cieslar-Pobuda A, Hu X, Bordin DL, Staerk J, Valen E, Schmierer B, Varjosalo M, Taipale J, Haapaniemi E (2021)
   Rapid genome editing by CRISPR-Cas9-POLD3 fusion
   Elife, 10
   DOI 10.7554/eLife.75415, PubMed 34898428
7. Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
   The expressed mutational landscape of microsatellite stable colorectal cancers
   Genome Med, 13 (1), 142
   DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Publications 2020

1. Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020)
   Accurate 3-gene-signature for early diagnosis of liposarcoma progression
   Clin Sarcoma Res, 10, 4
   DOI 10.1186/s13569-020-0126-1, PubMed 32158531
2. Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
   Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
   Blood Adv, 4 (9), 1859-1866
   DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

1. Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O (2019)
   ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
   Sci Rep, 9 (1), 17471
   DOI 10.1038/s41598-019-53917-5, PubMed 31767937
2. Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
   Remodeling of secretory lysosomes during education tunes functional potential in NK cells
   Nat Commun, 10 (1), 514
   DOI 10.1038/s41467-019-08384-x, PubMed 30705279
3. Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
   Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
   Cells, 8 (2)
   DOI 10.3390/cells8020189, PubMed 30795553
4. Namløs HM, Boye K, Meza-Zepeda LA (2019)
   Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
   Mol Aspects Med, 72, 100827
   DOI 10.1016/j.mam.2019.10.004, PubMed 31703948
5. Pashov A, Shivarov V, Hadzhieva M, Kostov V, Ferdinandov D, Heintz KM, Pashova S, Todorova M, Vassilev T, Kieber-Emmons T, Meza-Zepeda LA, Hovig E (2019)
   Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries
   Front Immunol, 10, 2796
   DOI 10.3389/fimmu.2019.02796, PubMed 31849974

Publications 2018

1. Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE (2018)
   Patterns of genomic evolution in advanced melanoma
   Nat Commun, 9 (1), 2665
   DOI 10.1038/s41467-018-05063-1, PubMed 29991680
2. Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
   Preclinical Evaluation of Vemurafenib as Therapy for BRAF^V600E Mutated Sarcomas
   Int J Mol Sci, 19 (4)
   DOI 10.3390/ijms19040969, PubMed 29570692
3. Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA (2018)
   Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
   PLoS One, 13 (5), e0197456
   DOI 10.1371/journal.pone.0197456, PubMed 29771965
4. Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
   Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
   Eur Urol, 75 (3), 498-505
   DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068
5. Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
   Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
   Mol Cancer Ther, 17 (11), 2473-2480
   DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488
6. Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
   Sample-Index Misassignment Impacts Tumour Exome Sequencing
   Sci Rep, 8 (1), 5307
   DOI 10.1038/s41598-018-23563-4, PubMed 29593270

Publications 2017

1. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
   Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
   Mol Cancer, 16 (1), 116
   DOI 10.1186/s12943-017-0691-y, PubMed 28683746
2. Chymkowitch P, P AN, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2017)
   Corrigendum: Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
   Genome Res, 27 (2), 334
   DOI 10.1101/gr.218370.116, PubMed 28148563
3. Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E (2017)
   Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
   Sci Rep, 7 (1), 9655
   DOI 10.1038/s41598-017-10189-1, PubMed 28848235
4. Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
   High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
   Int J Cancer, 141 (1), 184-190
   DOI 10.1002/ijc.30726, PubMed 28387924
5. Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017)
   Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
   BMC Cancer, 17 (1), 29
   DOI 10.1186/s12885-016-2992-8, PubMed 28061772
6. Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
   Monitoring multiple myeloma by quantification of recurrent mutations in serum
   Haematologica, 102 (7), 1266-1272
   DOI 10.3324/haematol.2016.160564, PubMed 28385781
7. Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
   Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
   Genome Med, 9 (1), 46
   DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

1. Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
   Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
   PLoS One, 11 (9), e0163859
   DOI 10.1371/journal.pone.0163859, PubMed 27685995
2. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
   TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
   Front Genet, 7, 85
   DOI 10.3389/fgene.2016.00085, PubMed 27242894
3. Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
   Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
   Oncotarget, 7 (34), 54583-54595
   DOI 10.18632/oncotarget.10518, PubMed 27409346
4. Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA (2016)
   Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
   Oncotarget, 7 (5), 5273-88
   DOI 10.18632/oncotarget.6567, PubMed 26672768
5. Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
   VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
   Genes Chromosomes Cancer, 55 (11), 890-901
   DOI 10.1002/gcc.22388, PubMed 27311012

Publications 2015

1. Chymkowitch P, Nguéa AP, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015)
   Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
   Genome Res, 25 (6), 897-906
   DOI 10.1101/gr.185793.114, PubMed 25800674
2. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
   Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
   Genome Biol, 16 (1), 7
   DOI 10.1186/s13059-014-0558-0, PubMed 25650807
3. Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C et al. (2015)
   Genomic landscape of liposarcoma
   Oncotarget, 6 (40), 42429-44
   DOI 10.18632/oncotarget.6464, PubMed 26643872
4. Lilleby W, Vlatkovic L, Meza-Zepeda LA, Revheim ME, Hovig E (2015)
   Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report
   J Med Case Rep, 9, 281
   DOI 10.1186/s13256-015-0749-7, PubMed 26654961
5. Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
   BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
   Blood Cancer J, 5 (3), e299
   DOI 10.1038/bcj.2015.24, PubMed 25794135
6. Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
   Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
   Oncotarget, 6 (4), 2451-65
   DOI 10.18632/oncotarget.3235, PubMed 25669981

Publications 2014

1. Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014)
   Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model
   Mol Cancer, 13, 93
   DOI 10.1186/1476-4598-13-93, PubMed 24885297
2. Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014)
   Performance comparison of four exome capture systems for deep sequencing
   BMC Genomics, 15 (1), 449
   DOI 10.1186/1471-2164-15-449, PubMed 24912484
3. Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014)
   The architecture and evolution of cancer neochromosomes
   Cancer Cell, 26 (5), 653-67
   DOI 10.1016/j.ccell.2014.09.010, PubMed 25517748
4. Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA (2014)
   The regulatory landscape of osteogenic differentiation
   Stem Cells, 32 (10), 2780-93
   DOI 10.1002/stem.1759, PubMed 24898411
5. Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014)
   Generation and characterization of an immortalized human mesenchymal stromal cell line
   Stem Cells Dev, 23 (19), 2377-89
   DOI 10.1089/scd.2013.0599, PubMed 24857590

Publications 2013

1. Herlofsen SR, Bryne JC, Høiby T, Wang L, Issner R, Zhang X, Coyne MJ, Boyle P, Gu H, Meza-Zepeda LA, Collas P, Mikkelsen TS, Brinchmann JE (2013)
   Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells
   BMC Genomics, 14, 105
   DOI 10.1186/1471-2164-14-105, PubMed 23414147
2. Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM (2013)
   IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
   BMC Cancer, 13, 245
   DOI 10.1186/1471-2407-13-245, PubMed 23688189
3. Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O (2013)
   Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
   Br J Cancer, 109 (8), 2228-36
   DOI 10.1038/bjc.2013.549, PubMed 24064976
4. Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013)
   Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
   Transl Oncol, 6 (5), 546-53
   DOI 10.1593/tlo.13457, PubMed 24151535
5. Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F (2013)
   Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program
   PLoS One, 8 (4), e61910
   DOI 10.1371/journal.pone.0061910, PubMed 23613970
6. Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
   Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
   PLoS One, 8 (6), e66165
   DOI 10.1371/journal.pone.0066165, PubMed 23824282

Publications 2012

1. Bjørnstad LG, Meza TJ, Otterlei M, Olafsrud SM, Meza-Zepeda LA, Falnes PØ (2012)
   Human ALKBH4 interacts with proteins associated with transcription
   PLoS One, 7 (11), e49045
   DOI 10.1371/journal.pone.0049045, PubMed 23145062
2. Chymkowitch P, Eldholm V, Lorenz S, Zimmermann C, Lindvall JM, Bjørås M, Meza-Zepeda LA, Enserink JM (2012)
   Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes
   Proc Natl Acad Sci U S A, 109 (26), 10450-5
   DOI 10.1073/pnas.1200067109, PubMed 22689984
3. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA (2012)
   Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma
   PLoS One, 7 (11), e48262
   DOI 10.1371/journal.pone.0048262, PubMed 23144859
4. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM (2012)
   Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data
   Genes Chromosomes Cancer, 51 (7), 696-706
   DOI 10.1002/gcc.21956, PubMed 22454324
5. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012)
   Modulation of the osteosarcoma expression phenotype by microRNAs
   PLoS One, 7 (10), e48086
   DOI 10.1371/journal.pone.0048086, PubMed 23133552
6. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O (2012)
   Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
   Cancer, 119 (5), 1013-22
   DOI 10.1002/cncr.27837, PubMed 23165797
7. Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, Meza-Zepeda LA, Jahnsen FL, Smidt H, Johansen FE (2012)
   Epithelial-microbial crosstalk in polymeric Ig receptor deficient mice
   Eur J Immunol, 42 (11), 2959-70
   DOI 10.1002/eji.201242543, PubMed 22865203
8. Skotheim RI, Meza-Zepeda LA, Hovig E, Lønning PE, Lothe RA, Myklebost O (2012)
   [Genome sequencing for personalized cancer treatment]
   Tidsskr Nor Laegeforen, 132 (21), 2406-8
   DOI 10.4045/tidsskr.12.0784, PubMed 23160594

Publications 2011

1. Dahlback HS, Brandal P, Krossnes BK, Fric R, Meling TR, Meza-Zepeda LA, Danielsen HE, Heim S (2011)
   Multiple chromosomal monosomies are characteristic of giant cell ependymoma
   Hum Pathol, 42 (12), 2042-6
   DOI 10.1016/j.humpath.2011.02.012, PubMed 21683982
2. Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
   Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
   BMC Cancer, 11, 455
   DOI 10.1186/1471-2407-11-455, PubMed 22014070
3. Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011)
   Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
   Cancer, 118 (2), 558-70
   DOI 10.1002/cncr.26276, PubMed 21713766
4. Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM (2011)
   mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
   BMC Med Genomics, 4, 66
   DOI 10.1186/1755-8794-4-66, PubMed 21933437
5. Reikvam DH, Erofeev A, Sandvik A, Grcic V, Jahnsen FL, Gaustad P, McCoy KD, Macpherson AJ, Meza-Zepeda LA, Johansen FE (2011)
   Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression
   PLoS One, 6 (3), e17996
   DOI 10.1371/journal.pone.0017996, PubMed 21445311
6. Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O (2011)
   Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222
   Stem Cells Dev, 21 (6), 873-83
   DOI 10.1089/scd.2010.0503, PubMed 21756067

Publications 2010

1. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
   Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
   Blood, 116 (9), 1489-97
   DOI 10.1182/blood-2010-03-272278, PubMed 20505157
2. Henriksen J, Stabell M, Meza-Zepeda LA, Lauvrak SA, Kassem M, Myklebost O (2010)
   Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells
   BMC Cancer, 10, 329
   DOI 10.1186/1471-2407-10-329, PubMed 20576167
3. Kresse SH, Ohnstad HO, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2010)
   DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation
   PLoS One, 5 (11), e15378
   DOI 10.1371/journal.pone.0015378, PubMed 21085701
4. Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, Myklebost O, Meza-Zepeda LA (2010)
   Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours
   BMC Res Notes, 3, 223
   DOI 10.1186/1756-0500-3-223, PubMed 20691109
5. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010)
   Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort
   Genes Chromosomes Cancer, 49 (1), 40-51
   DOI 10.1002/gcc.20717, PubMed 19787792

Publications 2009

1. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA (2009)
   LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
   Genes Chromosomes Cancer, 48 (8), 679-93
   DOI 10.1002/gcc.20675, PubMed 19441093
2. Lehne G, Grasmo-Wendler UH, Berner JM, Meza-Zepeda LA, Adamsen BL, Flack A, Reiner A, Clausen OP, Hovig E, Myklebost O (2009)
   Upregulation of stem cell genes in multidrug resistant K562 leukemia cells
   Leuk Res, 33 (10), 1379-85
   DOI 10.1016/j.leukres.2009.03.028, PubMed 19394083
3. Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M (2009)
   OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
   Leuk Res, 33 (12), 1670-7
   DOI 10.1016/j.leukres.2009.03.001, PubMed 19395026

Publications 2008

1. Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2008)
   DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH
   Mol Cancer, 7, 48
   DOI 10.1186/1476-4598-7-48, PubMed 18522746
2. Larsen E, Kleppa L, Meza TJ, Meza-Zepeda LA, Rada C, Castellanos CG, Lien GF, Nesse GJ, Neuberger MS, Laerdahl JK, William Doughty R, Klungland A (2008)
   Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants
   Cancer Res, 68 (12), 4571-9
   DOI 10.1158/0008-5472.CAN-08-0168, PubMed 18559501
3. Lybaek H, Meza-Zepeda LA, Kresse SH, Høysaeter T, Steen VM, Houge G (2008)
   Array-CGH fine mapping of minor and cryptic HR-CGH detected genomic imbalances in 80 out of 590 patients with abnormal development
   Eur J Hum Genet, 16 (11), 1318-28
   DOI 10.1038/ejhg.2008.78, PubMed 18461090
4. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
   GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
   Genome Biol, 9 (5), R86
   DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
5. Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P (2008)
   High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence
   J Cell Mol Med, 12 (2), 553-63
   DOI 10.1111/j.1582-4934.2007.00146.x, PubMed 18419597
6. Roman E, Meza-Zepeda LA, Kresse SH, Myklebost O, Vasstrand EN, Ibrahim SO (2008)
   Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization
   Oncol Rep, 20 (4), 825-43
   DOI 10.3892/or_00000080, PubMed 18813824

Publications 2007

1. Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B (2007)
   Lymphomas can develop from B cells chronically helped by idiotype-specific T cells
   J Exp Med, 204 (5), 1181-91
   DOI 10.1084/jem.20061220, PubMed 17485509

Publications 2006

1. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namløs HM, Wang J, Kristiansen BE, Myklebost O (2006)
   Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
   Cancer Res, 66 (18), 8984-93
   DOI 10.1158/0008-5472.CAN-06-1972, PubMed 16982739
2. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
   DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
   Anticancer Res, 26 (3A), 1909-16
   PubMed 16827124
3. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
   Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
   Leukemia, 20 (3), 539-42
   DOI 10.1038/sj.leu.2404094, PubMed 16437153

Publications 2005

1. Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, Myklebost O, Suo Z, Mu D, Deangelis PM, Stokke T (2005)
   Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas
   Leukemia, 19 (12), 2313-23
   DOI 10.1038/sj.leu.2403954, PubMed 16193090
2. Kresse SH, Berner JM, Meza-Zepeda LA, Gregory SG, Kuo WL, Gray JW, Forus A, Myklebost O (2005)
   Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH
   Mol Cancer, 4, 39
   DOI 10.1186/1476-4598-4-39, PubMed 16274472

Publications 2004

1. Nilbert M, Meza-Zepeda LA, Francis P, Berner JM, Namløs HM, Fernebro J, Myklebost O (2004)
   Lessons from genetic profiling in soft tissue sarcomas
   Acta Orthop Scand Suppl, 75 (311), 35-50
   DOI 10.1080/00016470410001708310, PubMed 15188664
2. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N (2004)
   Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas
   Int J Cancer, 109 (3), 363-9
   DOI 10.1002/ijc.11716, PubMed 14961574
3. Wang J, Meza-Zepeda LA, Kresse SH, Myklebost O (2004)
   M-CGH: analysing microarray-based CGH experiments
   BMC Bioinformatics, 5, 74
   DOI 10.1186/1471-2105-5-74, PubMed 15189572

Publications 2002

1. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
   Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
   Oncogene, 21 (14), 2261-9
   DOI 10.1038/sj.onc.1205339, PubMed 11948409
2. Meza TJ, Stangeland B, Mercy IS, Skårn M, Nymoen DA, Berg A, Butenko MA, Håkelien AM, Haslekås C, Meza-Zepeda LA, Aalen RB (2002)
   Analyses of single-copy Arabidopsis T-DNA-transformed lines show that the presence of vector backbone sequences, short inverted repeats and DNA methylation is not sufficient or necessary for the induction of transgene silencing
   Nucleic Acids Res, 30 (20), 4556-66
   DOI 10.1093/nar/gkf568, PubMed 12384603

Publications 2001

1. Forus A, Bjerkehagen B, Sirvent N, Meza-Zepeda LA, Coindre JM, Berner JM, Myklebost O, Pedeutour F (2001)
   A well-differentiated liposarcoma with a new type of chromosome 12-derived markers
   Cancer Genet Cytogenet, 131 (1), 13-8
   DOI 10.1016/s0165-4608(01)00516-7, PubMed 11734312
2. Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
   Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
   Oncogene, 20 (47), 6881-90
   DOI 10.1038/sj.onc.1204874, PubMed 11687967
3. Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O (2001)
   Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases
   Cancer Genet Cytogenet, 125 (2), 100-11
   DOI 10.1016/s0165-4608(00)00369-1, PubMed 11369052
4. Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O (2001)
   Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions
   Genes Chromosomes Cancer, 31 (3), 264-73
   DOI 10.1002/gcc.1143, PubMed 11391797

Publications 1999

1. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
   Expression of a novel factor in human breast cancer cells with metastatic potential
   Cancer Res, 59 (18), 4675-80
   PubMed 10493524

Publications 1998

1. Forus A, Berner JM, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad O, Myklebost O (1998)
   Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas
   Br J Cancer, 78 (4), 495-503
   DOI 10.1038/bjc.1998.521, PubMed 9716033

Publications 1997

1. Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O (1997)
   HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas
   Oncogene, 14 (24), 2935-41
   DOI 10.1038/sj.onc.1201135, PubMed 9205100